NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.27 +0.15 (+2.93 %)
(As of 08/20/2018 09:07 AM ET)
Previous Close$5.12
Today's Range$5.1090 - $5.31
52-Week Range$4.71 - $15.40
Volume58,555 shs
Average Volume168,383 shs
Market Capitalization$71.78 million
P/E Ratio-0.93
Dividend YieldN/A
Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.45
Quick Ratio3.45


Trailing P/E Ratio-0.93
Forward P/E Ratio-1.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$144.27 million
Price / Sales0.49
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book0.73


EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-60.33%
Return on Assets-42.77%


Outstanding Shares13,340,000
Market Cap$71.78 million

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Merrimack Pharmaceuticals.

What price target have analysts set for MACK?

2 brokerages have issued 1 year price objectives for Merrimack Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for Merrimack Pharmaceuticals.

What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 55)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 55)

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Headlines about MACK stock have trended somewhat positive on Monday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media and rumor sentiment score of 0.20 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Merrimack Pharmaceuticals.

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (4.75%), Dimensional Fund Advisors LP (3.51%), Wittenberg Investment Management Inc. (1.90%), BlackRock Inc. (1.89%), Connor Clark & Lunn Investment Management Ltd. (1.31%) and Millennium Management LLC (1.28%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Which major investors are selling Merrimack Pharmaceuticals stock?

MACK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Which major investors are buying Merrimack Pharmaceuticals stock?

MACK stock was acquired by a variety of institutional investors in the last quarter, including Newtyn Management LLC, Wittenberg Investment Management Inc., Dimensional Fund Advisors LP, Clearline Capital LP, Paloma Partners Management Co, LMR Partners LLP, Millennium Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $5.27.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $71.78 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]

MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel